Myopia Induced after Systemic Chemotherapy with Docetaxel
نویسندگان
doi
10.22037/joos.v8i4.48648چکیده
Transient myopia is an unreported toxicity of docetaxel. We report an unexpected development of myopia following systemic chemotherapy with docetaxel. A 38-year-old woman undergoing chemotherapy for breast cancer received docetaxel every two weeks. Prior to chemotherapy, she had no visual impairments, ocular disorders, or other comorbidities. After seven cycles of systemic chemotherapy, she began experiencing visual impairment. Her spherical equivalent refractive errors were -2.00 D in the right eye and -1.63 D in the left eye. Uncorrected visual acuity was 0.42 logMAR in the right eye and 0.3 logMAR in the left eye, both correctable to 0 logMAR. At a 4-week follow-up after cessation of chemotherapy, her vision gradually recovered. To our knowledge this is the first reported case of docetaxel induced myopia in a patient undergoing cancer treatment in the English literature, underscoring the need for clinicians to be aware of this potential ocular toxicity.